Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527124 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00527124: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00527124 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 57 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00527124, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well giving docetaxel and prednisone together with or without cediranib works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel together with prednisone, with or without cediranib, may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG prednisone
- DRUG docetaxel
- DRUG cediranib maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527124
The ClinicalTrials.gov registry entry for NCT00527124 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00527124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527124 about?
NCT00527124 is a clinical study titled "Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy". This randomized phase II trial is studying how well giving docetaxel and prednisone together with or without cediranib works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different w...
What is the current status of trial NCT00527124?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2007-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00527124?
The interventions under investigation include: laboratory biomarker analysis (OTHER), prednisone (DRUG), docetaxel (DRUG), cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00527124?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.